Skip to main content
Top
Published in: Experimental Hematology & Oncology 1/2018

Open Access 01-12-2018 | Rapid communication

Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies

Authors: Julien Magne, Alizée Jenvrin, Adrien Chauchet, Olivier Casasnovas, Anne Donzel, Laurence Jego, Bernard Aral, Julien Guy, Nathalie Nadal, Dewi Vernerey, Patrick Callier, Francine Garnache-Ottou, Christophe Ferrand

Published in: Experimental Hematology & Oncology | Issue 1/2018

Login to get access

Abstract

Background

Expression of SRY [sex-determining region Y]-box11 (SOX11) is specific to mantle cell lymphoma (MCL) and contributes, in conjunction with immunoglobulin variable heavy chain gene mutation status, to the identification of two forms of this disease.

Methods

The aim of this report was firstly, to design an easy and suitable RT-qPCR method to quantify SOX11 mRNA expression in mantle cell lymphoma and other B cell malignancies with the proper reference gene; secondly, to define the best threshold of relative quantity of SOX11 mRNA in order to reach the best compromise between sensitivity and specificity.

Results

For best discrimination of MCL and non-MCL groups we determined an area under the curve (AUC) of 0.9750 and a threshold of 1.76 with 100% sensitivity and 88% specificity. AUC and threshold values of respectively 0.91/1.346 [87% sensitivity, 80% specificity] and 0.9525/1.7120 [100% sensitivity, 88% specificity] for GAPDH and RPLP0 respectively denote that the RPLP0 reference gene alone is sufficient for PCR housekeeping gene.

Conclusion

This work describes an RT-qPCR assay for SOX11 expression in order to better characterize MCL at diagnosis. Further studies on larger cohorts are needed to evaluate this molecular tool, especially for the follow-up of minimal residual disease.
Appendix
Available only for authorised users
Literature
3.
4.
go back to reference Vegliante MC, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013;121(12):2175–85.CrossRefPubMed Vegliante MC, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013;121(12):2175–85.CrossRefPubMed
5.
go back to reference Shepherd JH, et al. The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget. 2016;7(11):13106–21.CrossRefPubMedPubMedCentral Shepherd JH, et al. The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget. 2016;7(11):13106–21.CrossRefPubMedPubMedCentral
6.
7.
go back to reference Bea S, Amador V. Role of SOX11 and genetic events cooperating with Cyclin D1 in mantle cell lymphoma. Curr Oncol Rep. 2017;19(6):43.CrossRefPubMed Bea S, Amador V. Role of SOX11 and genetic events cooperating with Cyclin D1 in mantle cell lymphoma. Curr Oncol Rep. 2017;19(6):43.CrossRefPubMed
9.
go back to reference Wasik AM, et al. Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma. Leuk Lymphoma. 2015;56(5):1425–31.CrossRefPubMed Wasik AM, et al. Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma. Leuk Lymphoma. 2015;56(5):1425–31.CrossRefPubMed
10.
go back to reference Lord M, et al. The utility of mRNA analysis in defining SOX11 expression levels in mantle cell lymphoma and reactive lymph nodes. Haematologica. 2015;100(9):e369–72.CrossRefPubMedPubMedCentral Lord M, et al. The utility of mRNA analysis in defining SOX11 expression levels in mantle cell lymphoma and reactive lymph nodes. Haematologica. 2015;100(9):e369–72.CrossRefPubMedPubMedCentral
12.
go back to reference Bustin SA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611–22.CrossRefPubMed Bustin SA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611–22.CrossRefPubMed
13.
go back to reference Roisman A, et al. SOX11 expression in chronic lymphocytic leukemia correlates with adverse prognostic markers. Tumour Biol. 2015;36(6):4433–40.CrossRefPubMed Roisman A, et al. SOX11 expression in chronic lymphocytic leukemia correlates with adverse prognostic markers. Tumour Biol. 2015;36(6):4433–40.CrossRefPubMed
15.
go back to reference Andersen NS, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol. 2009;27(26):4365–70.CrossRefPubMed Andersen NS, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol. 2009;27(26):4365–70.CrossRefPubMed
16.
go back to reference Wang M, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017;10(1):171.CrossRefPubMedPubMedCentral Wang M, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017;10(1):171.CrossRefPubMedPubMedCentral
17.
go back to reference Gamonet C, et al. New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. Exp Hematol Oncol. 2015;5:7.CrossRefPubMed Gamonet C, et al. New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. Exp Hematol Oncol. 2015;5:7.CrossRefPubMed
18.
go back to reference Nordstrom L, et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma–a nordic lymphoma group study. Br J Haematol. 2014;166(1):98–108.CrossRefPubMedPubMedCentral Nordstrom L, et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma–a nordic lymphoma group study. Br J Haematol. 2014;166(1):98–108.CrossRefPubMedPubMedCentral
Metadata
Title
Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies
Authors
Julien Magne
Alizée Jenvrin
Adrien Chauchet
Olivier Casasnovas
Anne Donzel
Laurence Jego
Bernard Aral
Julien Guy
Nathalie Nadal
Dewi Vernerey
Patrick Callier
Francine Garnache-Ottou
Christophe Ferrand
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Experimental Hematology & Oncology / Issue 1/2018
Electronic ISSN: 2162-3619
DOI
https://doi.org/10.1186/s40164-018-0097-6

Other articles of this Issue 1/2018

Experimental Hematology & Oncology 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine